Market Newsdesk

Dow to participate in J.P. Morgan Industrials Conference 2021

MIDLAND, Mich.–(BUSINESS WIRE)–Howard Ungerleider, president and chief financial officer, Dow Inc. (NYSE: DOW), will participate in a virtual fireside chat during the J.P. Morgan 2021 Industrials Conference on Tuesday, March 16 at 9:40 a.m. ET.

Dow invites investors to join the live webcast through its website. A replay and transcript will also be available within 48 hours following the event.

About Dow

Dow combines global breadth, asset integration and scale, focused innovation and leading business positions to achieve profitable growth. The Company’s ambition is to become the most innovative, customer centric, inclusive and sustainable materials science company, with a purpose to deliver a sustainable future for the world through our materials science expertise and collaboration with our partners. Dow’s portfolio of plastics, industrial intermediates, coatings and silicones businesses delivers a broad range of differentiated science-based products and solutions for its customers in high-growth market segments, such as packaging, infrastructure, mobility and consumer care. Dow operates 106 manufacturing sites in 31 countries and employs approximately 35,700 people. Dow delivered sales of approximately $39 billion in 2020. References to Dow or the Company mean Dow Inc. and its subsidiaries. For more information, please visit www.dow.com or follow @DowNewsroom on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005412/en/

Investors:

Pankaj Gupta

[email protected]

+1 989-638-5265

 

Media:

Kyle Bandlow

[email protected]

+1 989-638-2417

KEYWORDS: United States North America Michigan

INDUSTRY KEYWORDS: Packaging Engineering Chemicals/Plastics Manufacturing

MEDIA:

Logo

ImmunityBio Announces Positive Interim Phase I Safety Data of hAd5 T-Cell COVID-19 Vaccine Candidate in Oral and Sublingual Formulations

• Safety assessments completed for first 12 participants and no serious adverse events (SAEs) reported; trials expected to be fully enrolled in Q2
• First COVID-19 vaccine trials designed to deliver both S and N SARS-CoV-2 viral proteins via multiple routes—subcutaneous, sublingual, and oral

• Pre-clinical data from SARS-CoV-2 challenge study involving subcutaneous and oral immunization shows ImmunityBio’s lead hAd5-COVID-19 T-cell vaccine candidate is protective in non-human primates (NHP) against high SARS-CoV-2 titer exposures
• Robust T cell and Memory B cell response to virus challenge results in inhibition of virus growth in nose and lungs with subcutaneous/oral vaccine combination in NHP study

CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it has met the safety requirements for the first 12 participants in its Phase Ib human adenovirus (hAd5)-based T-cell COVID-19 vaccine trials in sublingual and oral formulations. The independent Safety Review Committee recommended the study continue with no modifications to the trial design. The trials, which will involve 80 participants, are expected to be fully enrolled in Q2.

The two U.S. Phase Ib trials are studying a combination of subcutaneous/ sublingual (under the tongue) (NCT04591717) and subcutaneous/oral (NCT04732468) formulations of ImmunityBio’s hAd5 T-cell COVID-19 vaccine candidate. Six participants have been dosed in each trial to date and the trial is anticipated to be fully enrolled in Q2 (prime plus boost). Based on the findings of these trials, the optimal combination of administration route and dose will be determined and entered into the Phase II/III design.

“We have not seen any serious adverse events in the participants who have received the hAd5 vaccine subcutaneously,” said Philip Robinson, M.D., the trial Principal Investigator and Medical Director of Infection Protection at Hoag Memorial Hospital Presbyterian in Newport Beach, California where the vaccine trials are being conducted. “Unlike most of the COVID-19 vaccines currently available, ImmunityBio’s hAd5 generates T-cell immunity, which is important for long duration immunity. Based on the results of subcutaneous/oral regimen in the nonhuman primate study where the vaccine provided complete protection against the virus challenge, we are excited to explore with ImmunityBio the potential for the vaccine to provide a T-cell boost to currently available vaccines. I am particularly encouraged by the immune response to the nucleocapsid protein, which may mean this vaccine will remain effective against the many emerging spike protein variants.”

Additional Data from BARDA-Funded Non-Human Primate Study

At the recent 2021 Conference on Retroviruses and Opportunistic Infections (CROI), ImmunityBio scientists presented pre-clinical data from SARS-CoV-2 challenge study involving subcutaneous and oral immunization that shows hAd5-COVID-19 T-cell vaccine candidate is completely protective in non-human primates against high SARS-CoV-2 titer exposures. This data is critically relevant to NCT0473468 mentioned above which is testing various combinations of subcutaneous and oral capsule administration in a Phase I clinical trial.

The vaccine-focused presentation, titled “Dual-Antigen Covid-19 Vaccination with Oral Boost Protects NHP from Viral Challenge”, detailed the results of a BARDA-funded COVID-19 challenge study in rhesus macaques assessing the antibody- and T cell-mediated immune responses to vaccination and protection against live SARS-CoV-2 challenge with ImmunityBio’s human adenovirus (hAd5)-based T-cell COVID-19 vaccine candidate in serial subcutaneous and oral administrations.

Key presentation results include:

• ImmunityBio’s vaccine candidate is a bivalent construct incorporating genes encoding a modified SARS-CoV-2 spike fusion protein and the SARS-CoV-2 nucleocapsid fusion protein. The second-generation, non-replicating hAd5 vector platform is being used has been manufactured in both subcutaneous and oral formulations.
• Ten rhesus macaques received either a subcutaneous (SC) prime dose followed by two oral boost doses (n=5) or two SC primes followed by one oral dose (n=5), with a two-subject placebo group.
• Neutralizing anti-spike antibodies and activated T cells activated against both the spike and nucleocapsid proteins were detected.
• Following a high-titer (106 TCID50) viral challenge, viral replication was assessed in nasal and respiratory passages.
• In all vaccinated rhesus macaques, investigators observed inhibition of viral replication in both lung and nasal passages within 24 hours of viral challenge, with viral load undetectable within 7 days compared to placebo controls. Enhanced antibody neutralization was noted in the days following the challenge, suggesting that memory B cells had been activated at the time of dosing.
• ImmunityBio’s COVID-19 vaccine candidate protects non-human primates from high-titer SARS-CoV-2 challenge when administered as subcutaneous prime with oral boost administration.
• The efficacy of the oral capsule formulation of the vaccine candidate is especially encouraging, as its stability at room temperate would facilitate cold chain-free vaccine distribution around the world.

About ImmunityBio

ImmunityBio is a leading late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company’s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term “immunological memory.”

ImmunityBio has an unparalleled immunotherapy pipeline with more than 40 clinical trials (company sponsored or investigator initiated)—of which 25 are at Phase II and III stage of development—across 19 indications in solid and liquid cancers and infectious diseases. Currently 17 first-in human immunotherapy agents are in clinical testing and, to date, over 1,800 patients have been studied with our antibody cytokine fusion proteins, albumin chemo immunomodulators, Adeno and yeast vaccines and our off-the-shelf natural killer cell products. Anktiva™ (ImmunityBio’s lead cytokine infusion protein) is a novel interleukin-15 (IL-15) superagonist complex and has received Breakthrough Therapy and Fast Track Designations from the U.S. Food and Drug Administration (FDA) for BCG-unresponsive CIS non-muscle invasive bladder cancer (NMIBC).

The company’s platforms are based on the foundation of four separate modalities: Antibody cytokine fusion proteins, synthetic immunomodulators, second-generation human adenovirus (hAd5) and yeast vaccine technologies, and state-of-the-art, off-the-shelf natural killer cells, including autologous and allogenic cytokine-enhanced memory NK cells.

ImmunityBio is a leading producer of cryopreserved and clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The company has established GMP manufacturing capacity at scale with cutting-edge cell manufacturing expertise and ready-to-scale facilities, as well as extensive and seasoned R&D, clinical trial, and regulatory operations and development teams. For more information, please visit: www.immunitybio.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as “anticipates,” “believes,” “continues”, “could”, “estimates,” “expects,” “intends,” “may,” “plans,” “potential”, “predicts”, “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. These forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio’s management as well as assumptions made by and information currently available to ImmunityBio. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) potential adverse effects or changes to relationships with employees, suppliers or other parties resulting from the completion of the merger , (ii) the outcome of any legal proceedings that may be instituted against the parties and others related to the merger, (iii) unexpected costs, charges or expenses resulting from the merger, (iv) uncertainty of the expected financial performance of the combined company following completion of the merger, including the possibility that the expected synergies and value creation from the merger will not be realized or will not be realized within the expected time period, (v) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs, and the timing and success of any such continued preclinical and clinical development and planned regulatory submissions, (vi) inability to retain and hire key personnel, and (vii) the unknown future impact of the COVID-19 pandemic delay on certain clinical trial milestones and/or ImmunityBio’s operations or operating expenses. More details about these and other risks that may impact ImmunityBio’s business are described under the heading “Risk Factors” in the Company’s Form 8-K filed with the U.S. Securities and Exchange Commission (“SEC”) on March 10, 2021 and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC’s website at www.sec.gov. ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005272/en/

Investors

Sarah Singleton

ImmunityBio, Inc.

844-696-5235, Option 5

Media

Amy Jobe, Ph.D.

LifeSci Communications

315-879-8192

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Biotechnology Infectious Diseases Health Pharmaceutical Clinical Trials

MEDIA:

Logo

PURE Bioscience and LightHouse for the Blind and Visually Impaired – San Francisco Announce Successful Completion of FAA Evaluation

RANCHO CUCAMONGA, Calif.–(BUSINESS WIRE)–
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, and its General Services Administration (GSA) and AbilityOne partner LightHouse for the Blind and Visually Impaired – San Francisco (LightHouse), today announced the successful completion of a Federal Aviation Administration (FAA) evaluation of PURE Bioscience’s PURE Hard Surface sanitizer and disinfectant product for use in FAA locations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210315005265/en/

Following a vetting process which took several weeks, the FAA approved and announced that PURE Hard Surface was the only antimicrobial on the Environmental Protection Agency (EPA) List N (antimicrobials approved for use against COVID-19) authorized to be used in FAA locations such as airports, control towers, radar centers and regional control centers.

The lead scientist on the evaluation committee for the FAA stated: “The Federal Aviation Administration is one of 16 critical infrastructure sectors, meaning their assets, systems, and networks, whether physical or virtual, are considered so vital to the United States that their incapacitation or destruction would have a debilitating effect on security, national economic security, or national public health or safety. The arrival of COVID-19 presented unique challenges to keeping FAA personnel and equipment safe and functional and planes moving safely through the skies. Balancing the regulatory frameworks of the EPA, the CDC and the FDA, combined with issues of materials compatibility (e.g., does it harm screen coatings?), was a major technical effort for which PURE Hard Surface was uniquely prepared. Rigorous chemical and physical testing identified only one product out of hundreds on the EPA List N that met all the FAA criteria (no harm to people or equipment, no warning labels or personal protective equipment required, no odors, 30-second contact time for human coronavirus, product volume available on demand, rated for Emerging Viral Pathogens, secure supply chain and ease of use). PURE Hard Surface met and exceeded all required criteria.”

Following the success of a FAA pilot testing program, the FAA is requiring its janitorial service providers for FAA locations to sanitize daily using PURE Hard Surface. To date, there are 85 FAA locations, including major airports, that are sanitized with PURE Hard Surface.

PURE’s Chief Executive Officer and President Tom Y. Lee said, “We are proud that our technology met the needs and requirements for the Federal Aviation Administration’s antimicrobial use. PURE Bioscience is honored to be a part of the overall effort to maintain critical U.S. infrastructure. Our partnership with LightHouse makes PURE Hard Surface available to all federal government agencies through the GSA as an AbilityOne product supporting the National Industries for the Blind. The chemistry and its attributes that led to approval by the FAA committee are the same that we offer to all our customers to effectively meet their antimicrobial needs, from schools and restaurants to food processing.”

LightHouse works to advance the skills, training and opportunities for people who are blind or visually impaired. Seventy-five percent of the workforce employed to ship, bottle, and blend PURE Bioscience products are blind or visually impaired. Senior Director of Operations Brandon Cox said, “People who are blind or visually impaired are at the core of what we do. Not only are we offering secure, at-market-rate employment opportunities for this community, but we are partnering with PURE Bioscience to provide an ethical, incredibly efficient, and safe product line. And all from the Sirkin Center, our new purpose-built manufacturing plant in Alameda, right here in the Bay Area.”

About LightHouse for the Blind and Visually Impaired – San Francisco

Headquartered in San Francisco, California, LightHouse for the Blind and Visually Impaired provides education, training, advocacy, and community for blind individuals in California and around the world. Its Sirkin Center social enterprise provides essential funds to support the education, recreation, and training needs of more than 3,000 blind people every year. The Sirkin Center is the largest blind-supporting social enterprise in California and is expecting to meet increasing demand for its products for governmental, commercial, and educational customers. The organization provides training in independence, equality, and self-reliance as well as blindness skills development, access to employment, education, government, information, recreation, transportation, and the environment.

About PURE Bioscience, Inc.

PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena. We provide solutions to combat the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented, stabilized ionic silver, and our initial products contain silver dihydrogen citrate, better known as SDC. This is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual bacterial protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and mitigation of bacterial resistance. PURE is headquartered in Rancho Cucamonga, California (San Bernardino metropolitan area). Additional information on PURE is available at www.purebio.com

Forward-looking Statements: Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Statements in this press release concerning the Company’s expectations (including with respect to Lighthouse and FAA), plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; economic and other disruptions resulting from COVID-19; acceptance of the Company’s current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests for PURE Control and PURE Hard Surface into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the Company’s ability to maintain relationships with its partners and other counterparties; the Company’s ability to generate sufficient revenues and reduce its operating expenses in order to reach profitability; the Company’s ability to raise the funding required to support its continued operations and the implementation of its business plan; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing and to expand its use in OLR poultry processing; competitive factors, including customer acceptance of the Company’s SDC-based products that are typically more expensive than existing treatment chemicals; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2020, Form 10-Q for the fiscal first quarter ended October 31, 2020 and Form 10-Q for the fiscal second quarter ended January 31, 2021. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005265/en/

Mark Elliott, VP Finance

PURE Bioscience, Inc.

Ph: 619-596-8600 ext: 116

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Other Transport Infectious Diseases Air Transport Other Travel Transportation Health General Health Travel

MEDIA:

Logo

Logo

SRAX Releases the Shelf Registration Feature on the Sequire Platform

LOS ANGELES–(BUSINESS WIRE)–
SRAX, Inc. (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, has announced the release of its Shelf Registration Feature. This new Sequire addition combines data and technology to provide actionable insights to public companies in regards to their shelf availability.

The new shelf registration feature joins many other unique and robust Sequire features such as warrant management, situation room, and shareholder surveys.

The shelf feature enables shelf eligible users to review and keep track of their shelf registration and current shelf availability. Included with this is the Shelf Prediction Tool: a real-time application to explore potential “market windows,” showing the impact of market volatility and thus improving funding plans.

Shelf Registration Feature benefits:

• Know what is available on your shelf at any time
• Continuous importing of all data in real time
• Seamless data additions for non-public share increases via the full-feature data editor
• Efficient, one-click predictions to explore the impact of market volatility

“This feature is one of many that is defining us as the premier operating system for public companies. Through providing issuers the tools they need to manage the entire public company experience, we are making executives’ lives easier,” said Christopher Miglino, Founder and CEO of SRAX. “As a public company that has the ability to file a Shelf, we are acutely aware of the calculations that go into determining the availability we have at any given time. The shelf is one of the most important financing options for public companies and we built this tool to help companies with everything they need to know about their availability. When companies are in baby shelf they have a need to understand where the price needs to be for them to be out of baby shelf and when they have full availability they need to understand what impact a new deal will have on their future availability,” added Miglino.

This feature brings additional value to the Sequire platform and is just the beginning of a series of features to be released in 2021.

For more information on Sequire and how it can help your company, visit mysequire.com.

About SRAX

SRAX (NASDAQ: SRAX) is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX, visit srax.com and mysequire.com.

Cautionary Statement Regarding Forward-Looking Information:

This news release contains “forward-looking statements” made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in our business, and our need for future capital. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in SRAX’s periodic reports filed with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Reports on Form 10-Q as well as and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005260/en/

Bri Kelvin

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Software Technology Professional Services Finance

MEDIA:

Logo

New Survey Shows Stress Over the Past Year Is Negatively Impacting the Quality of Sleep for Half of Americans

• Nationwide survey from ResMed finds sleep quality impacted more for women
• High prevalence of snoring and low concern for potential health impacts point to the need for increased sleep apnea awareness

SAN DIEGO–(BUSINESS WIRE)–
ResMed (NYSE: RMD, ASX: RMD), a world-leading digital health company, announced today the results of a nationwide survey of 1,000 adults, which revealed that for half of Americans, stress over the past year is negatively impacting the quality of their sleep – and many are ignoring sleep challenges that could point to a larger underlying health concern.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210315005242/en/

ResMed published the survey in conjunction with National Sleep Awareness Week (March 14-20) and World Sleep Day (March 19), and as part of Sleep for a Better Tomorrow, an education and outreach initiative to build awareness of the critical role good sleep plays in physical and mental health – and how to get our best sleep.

“COVID-19 has impacted all aspects of our lives, including our sleep health, leading many people to struggle to get the recommended seven to nine hours of sleep at night,” said Carlos M. Nunez, M.D., chief medical officer for ResMed.

Beyond the pervasive effects of stress, the survey found the impacts on sleep vary across gender and working arrangements.

• 35% of women reported worse sleep quality in the past year compared to just 26% of men. Women selected stress and anxiety as the most significant impacts on their sleep.
• More individuals working from home reported improved sleep quality since the pandemic began vs. those who haven’t worked from home (39% vs. 21%).
• Across all respondents, more than one-third say they are having a harder time falling asleep, and nearly one-third say they are sleeping less over the last year, and one-quarter started taking naps more often.

Snoring and sleep apnea

While COVID-related stresses are often noticeable, one of the biggest stealers of our sleep might be something we can’t easily detect: sleep apnea.

The survey revealed that more than one in two Americans say they snore, or a bed partner has told them they snore, yet 78% of those who snore aren’t concerned it could be related to an underlying health condition, despite snoring being a top symptom of sleep apnea. Additionally, nearly half of survey respondents said their doctor had not asked them about their sleep quality, reinforcing the importance of consumers being aware of the potential health impacts of poor sleep and acting on key sleep apnea symptoms such as snoring.

“While data show that stress and worry are key factors impacting many people’s sleep, now is an opportunity for everyone to take measure of all of the factors that could be impacting the quality of their sleep, which could include sleep disorders that can have negative long-term impacts to overall health,” said Nunez.

Everyone experiences a lousy night of sleep once in a while; however, those who experience ongoing sleep issues could be dealing with a more significant underlying health condition. Most survey respondents who snore overwhelmingly discount the potential health impacts, yet snoring is the most prevalent symptom of sleep apnea – one of the most common sleep disorders. Over 54 million adults in the U.S. have sleep apnea, but more than 80% don’t know they have it. Undiagnosed and untreated sleep apnea may increase your risk for developing other chronic and life-threatening conditions, including high blood pressure, heart disease, and Type 2 diabetes.

“Sleep apnea can impact all types of people from all walks of life, and while some people are more prone to have sleep apnea, it does not discriminate,” said Nunez. “If you snore, have been told you stop breathing in your sleep, or feel tired each day despite getting enough hours of sleep, ask your doctor if sleep apnea – which is 100% treatable at home – could be the cause.”

To learn more about ResMed’s sleep surveyor to take a free quiz about your risk for sleep apnea, visit SleepForBetterTomorrow.com.

About the Survey

The survey was conducted in February 2021 among 1,000 individuals 18 and older in the U.S. The survey was fielded using Qualtrics Insights Platform, and the panel was sourced from Lucid.

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005242/en/

For media

Jayme Rubenstein
+1 858.836.6798

[email protected]

For investors

Amy Wakeham

+1 858.836.5000

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Other Health Software General Health Hardware Data Management Medical Devices Technology Hospitals Biotechnology Nursing Other Technology Health

MEDIA:

Logo

Photo

35% of women report worse sleep quality in the past year vs. 26% of men (Graphic: Business Wire)

Photo

58% of Americans say they snore, yet 72% of those who snore aren’t concerned it could be related to an underlying health condition. (Graphic: Business Wire)

Photo

50% of Americans say stress or worry has negatively impacted their sleep over the past year. (Graphic: Business Wire)

Photo

Family sleeping (Photo: Business Wire)